Inc. magazine ranked Meridian Clinical Research 745 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies. Headquartered in Omaha, NE, Meridian is a multi-specialty site network with 36 sites nationwide. This is Meridian’s third consecutive ranking on the magazine’s list. The company ranked 1,145 in 2021, and 2,938 in 2020.
Nicole Osborn, Founder and CEO of Meridian, said the ranking is a significant milestone for the company, which now includes more than 600 employees. “The ranking showcases the incredible growth Meridian has achieved, as well as the strength of our industry partnerships as we continue to expand geographically and therapeutically,” said Osborn.
The company’s 2022 ranking reflects revenue growth from 2018 to 2021, a period during which Meridian has enrolled more participants year-over-year while expanding its site network and number of principal investigators. In that time, Meridian has opened more than a dozen new research locations and acquired additional sites through the acquisition of North Cliff Consultants, Sterling Research Group, and Regional Clinical Research. Since opening in Omaha in 1999, Meridian has enrolled more than 85,000 patients in 3,400 clinical trials.
Osborn attributes some of the sustained growth to a novel Strength In Numbers employee bonus program, which ties annual bonuses and performance metrics to a charitable giving budget. Meridian has donated almost $2.4 million to its communities, local fundraisers, and charitable organizations since 1999. The company’s charitable giving goal for 2022 is $750,000.
Complete results of the Inc. 5000 list, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at inc.com/inc5000. “The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work, and rising to the challenges of today.”
If you’re interested in joining a clinical trial at Meridian or want to sign up to learn about upcoming studies, visit mcrmed.com/find-study. To learn more about careers at Meridian, visit mcrmed.com/careers.
About Meridian Clinical Research
Meridian Clinical Research partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, and diagnostics that could improve human health and wellbeing. Founded in 1999, Meridian is a multi-specialty clinical research site network headquartered at its dedicated research center in Omaha, NE, and conducts Phase 1-4 clinical trials at investigative sites nationwide. Meridian supports research across numerous therapeutic areas and excels in high-volume vaccine trials. For more information, visit mcrmed.com.
More about Inc. and the Inc. 5000
Facebook, Chobani, Under Armour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000. Methodology: Companies on the 2022 Inc. 5000 are ranked according to percentage revenue growth from 2018 to 2021. To qualify, companies must have been founded and generating revenue by March 31, 2018. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2021. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2018 is $100,000; the minimum for 2021 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places. The top 500 companies on the Inc. 5000 are featured in Inc. magazine’s September issue. The entire Inc. 5000 can be found at inc.com/inc5000.
Read the press release on PR Web: https://www.prweb.com/releases/meridian_clinical_research_ranks_745_on_the_inc_5000_list_of_the_fastest_growing_private_companies_in_the_u_s/prweb18836481.htm